Finally, the surface markers CD69 and PD-1 were also found to be expressed on CD4+ T cells in metastatic tumors but the prognostic value of assessing these markers using immunohistochemistry or in situ IF remains to be demonstrated in melanoma (69). Here, CD4 is linked to melanoma.